Objective:To investigate the expression of SP70 in hunman ovarian cancer and its correlations with clinicopathological significance. Methods:A case-control study was conducted. Paraffin sections of tumor tissues from 65 patients with ovarian cancer and 30 patients with benign ovarian disease(15 benign ovarian tumor and 15 benign ovarian cyst) were collected. The expression of SP70 was examined by immunohistochemical staining. The results were scored by semiquantitative analysis. Statistical analysis was evaluated by chi-square test or Fisher exact test. The expression of SP70 in hunman ovarian cancer and their clinicopathological significance was analyzed. Relationship between SP70 and CA125 expression in ovarian cancer was analyzed by using Spearman rank correlation analysis. Results:The positive rate of SP70 in ovarian cancer was higher than that in benign ovarian disease (72.3% vs. 3.3%, P﹤0.05). The positive rate of SP70 in poor differentiation was also higher than that in well and moderate differentiation cancers(84.4% vs. 45.0%, P﹤0.05). Meanwhile,the high expression of SP70 in ovarian cancer between Ⅰ~Ⅱ stage and Ⅲ~Ⅳ stage was significantly different (94.1% vs. 64.6%, P﹤0.05). SP70 expression in patients with lymph node metastasis was very strong and there was significant difference between the former and that without lymph node metastasis (100% vs. 64.0%, P﹤0.05). The expression of SP70 and CA125 showed a complementary effect,but there was no significant correlation (r=0.039, P > 0.05). Conclusion:High expression of SP70 in ovarian cancer showed significant association with clinical stage,differentiation and lymph node metastasis. Therefore, it would be of some value in the evaluation of the diagnosis and prognosis of ovarian cancer. Joint detection of SP70 and CA125 can obviously improve the diagnostic sensitivity of ovarian cancer, having important clinical significance in early detection and diagnosis of ovarian cancer.